Cited 33 times in
MRP1 polymorphisms associated with citalopram response in patients with major depression
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김세주 | - |
dc.contributor.author | 김소원 | - |
dc.contributor.author | 이민구 | - |
dc.contributor.author | 이성희 | - |
dc.contributor.author | 이재면 | - |
dc.contributor.author | 이지현 | - |
dc.date.accessioned | 2015-04-23T16:34:22Z | - |
dc.date.available | 2015-04-23T16:34:22Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0271-0749 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/100828 | - |
dc.description.abstract | Multidrug resistance protein 1 (MRP1, ABCC1) transports antidepressive agents in the endothelial cells of the blood-brain barrier. Therefore, polymorphisms in the MRP1 gene may affect the treatment response of antidepressants. This study was aimed to identify the association between genetic variations in MRP1/ABCC1 and the therapeutic response to the antidepressant citalopram. One hundred and twenty-three patients who had been treated with citalopram monotherapy to control their major depressive disorder were recruited, and genotype data from 64 patients who had completed their 8-week follow-up were evaluated together with those from 100 controls. Nine MRP1 single nucleotide polymorphisms (SNPs) showing more than 5% allele frequency in the Korean population were analyzed. The c.4002G>A, a synonymous SNP in exon 28, showed a strong association with the remission state at 8 weeks (P = 0.005, odds ratio [OR], 4.7, 95% confidence interval [CI], 1.5 approximately 14.7). The c.4002G>A forms a linkage disequilibrium block with 3 other SNPs including c.5462T>A in the 3' untranslated region. Accordingly, the haplotype showed a significant association with the remission state (P = 0.014). Subsequent molecular studies also supported the association between these MRP1 polymorphisms and the citalopram response. Thus, kinetic studies using MRP1-enriched membrane vesicles revealed that citalopram is a substrate of MRP1 (Km = 1.99 microM, Vmax = 137 pmol/min per milligram protein). In addition, individuals with c.4002G>A or c.5462T>A polymorphisms showed higher MRP1 mRNA levels in peripheral blood cells. These results suggest that MRP1 polymorphisms may be a predictive marker of citalopram treatment in major depression. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 116~125 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Citalopram/therapeutic use* | - |
dc.subject.MESH | Depressive Disorder, Major/drug therapy* | - |
dc.subject.MESH | Depressive Disorder, Major/genetics* | - |
dc.subject.MESH | Depressive Disorder, Major/psychology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Gene Frequency/genetics | - |
dc.subject.MESH | Genetic Variation/genetics | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multidrug Resistance-Associated Proteins/genetics* | - |
dc.subject.MESH | Polymorphism, Single Nucleotide/genetics* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | MRP1 polymorphisms associated with citalopram response in patients with major depression | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Microbiology (미생물학) | - |
dc.contributor.googleauthor | Jung-Soo Lee | - |
dc.contributor.googleauthor | Young Mee Lee | - |
dc.contributor.googleauthor | Joo Young Kim | - |
dc.contributor.googleauthor | Hyun Woo Park | - |
dc.contributor.googleauthor | Sergio Grinstein | - |
dc.contributor.googleauthor | John Orlowski | - |
dc.contributor.googleauthor | Eunjoon Kim | - |
dc.contributor.googleauthor | Kyung Hwan Kim | - |
dc.contributor.googleauthor | Min Goo Lee | - |
dc.identifier.doi | 10.1097/JCP.0b013e3181d2ef42 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00604 | - |
dc.contributor.localId | A00622 | - |
dc.contributor.localId | A02781 | - |
dc.contributor.localId | A02876 | - |
dc.contributor.localId | A03071 | - |
dc.contributor.localId | A03217 | - |
dc.relation.journalcode | J01340 | - |
dc.identifier.eissn | 1533-712X | - |
dc.identifier.pmid | 20520284 | - |
dc.identifier.url | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00004714-201004000-00004&LSLINK=80&D=ovft | - |
dc.subject.keyword | MRP1/ABCC1 | - |
dc.subject.keyword | citalopram | - |
dc.subject.keyword | remission | - |
dc.subject.keyword | major depressive disorder | - |
dc.subject.keyword | ABC transporter | - |
dc.contributor.alternativeName | Kim, Se Joo | - |
dc.contributor.alternativeName | Kim, So Won | - |
dc.contributor.alternativeName | Lee, Min Goo | - |
dc.contributor.alternativeName | Lee, Sung Hee | - |
dc.contributor.alternativeName | Lee, Jae Myun | - |
dc.contributor.alternativeName | Lee, Ji Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Se Joo | - |
dc.contributor.affiliatedAuthor | Kim, So Won | - |
dc.contributor.affiliatedAuthor | Lee, Min Goo | - |
dc.contributor.affiliatedAuthor | Lee, Sung Hee | - |
dc.contributor.affiliatedAuthor | Lee, Jae Myun | - |
dc.contributor.affiliatedAuthor | Lee, Ji Hyun | - |
dc.citation.volume | 30 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 116 | - |
dc.citation.endPage | 125 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, Vol.30(2) : 116-125, 2010 | - |
dc.identifier.rimsid | 55246 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.